Conatus Pharmaceuticals Obtains $66,000,000 New Financing

  • Feed Type
  • Date
    7/25/2013
  • Company Name
    Conatus Pharmaceuticals
  • Mailing Address
    4365 Executive Drive San Diego, CA 92121
  • Company Description
    Conatus Pharmaceuticals (NASDAQ: CNAT) is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. We are developing our lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease.
  • Website
    http://www.conatuspharma.com
  • Transaction Type
    IPO
  • Transaction Amount
    $66,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes are on file with company statements at the SEC.
  • M&A Terms

By posting a comment, you agree to our terms and conditions.